tradingkey.logo

Corcept Therapeutics Inc <CORT.OQ> expected to post earnings of 43 cents a share - Earnings Preview

ReutersFeb 24, 2025 9:51 PM
  • Corcept Therapeutics Inc CORT.OQ CORT.O is expected to show a rise in quarterly revenue when it reports results on February 26 for the period ending December 31 2024

  • The Redwood City California-based company is expected to report a 46.7% increase in revenue to $198.686 million from $135.41 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Corcept Therapeutics Inc is for earnings of 43 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Corcept Therapeutics Inc is $95.50​, above​ its last closing price of $63.54. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

0.29

0.28

0.41

Beat

45.4

Jun. 30 2024

0.24

0.23

0.32

Beat

39.1

Mar. 31 2024

0.23

0.22

0.25

Beat

13.6​

Dec. 31 2023

0.27

0.26

0.28

Beat

8.5

​​Sep. 30 2023

0.23

0.22

0.28

Beat

28.2

Jun. 30 2023

0.15

0.15

0.25

Beat

66.7​

Mar. 31 2023

0.19

0.19

0.14

Missed

-27.6

Dec. 31 2022

0.23

0.23

0.14

Missed

-37.8

This summary was machine generated February 24 at 21:51 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI